Compare Charles River Laboratories Intl. Inc (CRL) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Charles River Laboratories Intl. Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Charles River Laboratories Intl. Inc trades at $303.14 (market cap $14.23B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.44 (market cap $296.92M). The key difference: Charles River Laboratories Intl. Inc is far larger — about 47.9× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| CRL | YMAG | |
|---|---|---|
Market Cap | $14.23B | $296.92M |
Volume | 1,176,885 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $310.77 | $15.68 |
52-Week Low | $149.93 | $10.76 |
Typical Hold Time | 33 Days | 62 Days |
Enterprise Value | $17.06B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
